In the responder group, both CD4+CD25+CD127loFoxP3+ Treg cells and PD-1+CD4+CD25+CD127loFoxP3+ Treg cells were significantly reduced (107).In NSCLC patients treated with anti-PD-1 antibodies, elevated baseline levels of circulating CD4+CCR9+, CD4+CCR10+, or CD8+CXCR4+ T cells were linked to poorer overall survival (15.7 vs. 35.9 months, HR 0.16, p = 0.003; 22.0 vs. not reached, HR 0.10, p = 0.003; and 22.0 vs. not reached, HR 0.29, p = 0.02) (108). The gene discussed is CD4; the disease is non-small cell lung carcinoma.